Location:
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Phone: (504) 613-3933
Event Time (Central Time):
12:15 PM – 12:45 PM — Registration and Lunch Buffet
12:45 PM – 2:15 PM — Educational Meeting
Meeting Room:
Empire Ballroom A (Level 2)
There is no registration fee for this event. However, preregistration is advised as seating is limited.
MODULE 1: Local and Systemic Therapeutic Considerations for Patients with Newly Diagnosed Advanced Ovarian Cancer (OC) — Dr Secord
Sample Community Oncologist Case PresentationA 61-year-old woman presents with lower abdominal pain and a 20-lb weight loss over the past 4 months. On physical examination, the patient appears ill and is noted to have moderate ascites. Laboratory results reveal a CA-125 of 1,200 U/mL, and imaging studies identify a 12-cm mass in the left ovary with multiple peritoneal nodules (up to 2 cm) and significant para-aortic adenopathy. Cytology from paracentesis on the ascites demonstrates malignant cells consistent with serous adenocarcinoma.
Sample Case Discussion QuestionsMODULE 2: Evolving Treatment Paradigms for Patients with Platinum-Sensitive Recurrent OC — Dr Monk
Sample Community Oncologist Case PresentationA 66-year-old woman diagnosed with a Stage IIC ovarian adenocarcinoma undergoes debulking surgery followed by 6 cycles of IV carboplatin/paclitaxel. Genetic testing reveals wild-type BRCA and no other genomic alterations. Eighteen months later the patient experiences a significant rise in her CA-125 levels, and subsequent imaging reveals disease progression in the pelvis. The patient is started on carboplatin/gemcitabine/bevacizumab and achieves a complete response by CA-125 and imaging studies.
Sample Case Discussion QuestionsMODULE 3: Patient- and Disease-Specific Considerations in the Management of Platinum-Resistant Recurrent OC — Dr Dizon
Sample Community Oncologist Case PresentationA 56-year-old woman diagnosed with Stage IIIC ovarian adenocarcinoma undergoes debulking surgery followed by 6 cycles of IV carboplatin/paclitaxel. Genetic counseling reveals a germline mutation in BRCA1. Eighteen months later the patient’s CA-125 rises dramatically, and imaging reveals disease in the pelvis, which is biopsy proven to be recurrent adenocarcinoma. The patient is started on carboplatin/pegylated liposomal doxorubicin (PLD) and achieves a partial response. She is subsequently placed on niraparib maintenance but approximately 3 months into treatment presents with symptomatic ascites and pleural effusions. Paracentesis and thoracentesis reveal malignant cells consistent with her original diagnosis.
Sample Case Discussion QuestionsMODULE 4: Novel Investigational Agents in Development for Patients with OC — Dr Martin
Sample Community Oncologist Case PresentationA 61-year-old woman diagnosed with BRCA1/2 mutation-negative, Stage IIIC OC receives 6 cycles of adjuvant carboplatin/paclitaxel. One year later her CA-125 starts to rise, and imaging reveals recurrent peritoneal disease. She then receives carboplatin/gemcitabine/bevacizumab, achieves a partial response and is placed on maintenance bevacizumab. Five months into her maintenance bevacizumab her disease recurs with a rising CA-125 and mild abdominal pain. The patient wants to be as aggressive as possible with treatment and is interested in experimental approaches.
Sample Case Discussion QuestionsTarget Audience:
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
Learning Objectives:
Upon completion of this activity, participants should be able to:
CME Credit Form:
A credit form will be given to each participant at the conclusion of this activity.
Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.
Supporters:
This activity is supported by educational grants from Genentech BioOncology, ImmunoGen Inc and Merck.
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Phone: (504) 613-3933
Meeting Room:
Empire Ballroom A (Level 2)
Directions:
The Hyatt Regency New Orleans hotel is the main venue for the SGO Annual Meeting on Women's Cancer.